TiGenix

Leuven, Belgium Founded: 2000 • Age: 26 yrs Acquired By Takeda
Allogeneic stem cell-based therapies targeting autoimmune, inflammatory and heart diseases.
Request Access

About TiGenix

TiGenix is a company based in Leuven (Belgium) founded in 2000 was acquired by Takeda in January 2018.. TiGenix has raised $19 million across 15 funding rounds from investors including Takeda Pharmaceuticals, RA Capital and Kreos Capital. TiGenix has completed 2 acquisitions, including Cellerix and Orthomimetics. TiGenix operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others.

  • Headquarter Leuven, Belgium
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $19 M (USD)

    in 15 rounds

  • Latest Funding Round
    $25.9 K (USD), Post-IPO

    Nov 16, 2017

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
    Cellerix

    & 1 more

  • Acquired by
    Takeda

    (Jan 05, 2018)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of TiGenix

TiGenix has successfully raised a total of $19M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25.9 thousand completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 15
  • Last Round Post-IPO — $25,902
  • First Round

    (05 Jan 2006)

  • Investors Count 15
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2017 Amount Post-IPO - TiGenix Valuation

investors

Mar, 2016 Amount Post-IPO - TiGenix Valuation

investors

Nov, 2015 Amount Post-IPO - TiGenix Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in TiGenix

TiGenix has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Takeda Pharmaceuticals, RA Capital and Kreos Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture debt is provided to growth-stage companies across multiple sectors.
Founded Year Domain Location
Brightlands Venture Partners is focused on venture capital investments.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by TiGenix

TiGenix has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cellerix and Orthomimetics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Resorbable implant for minimally invasive repair of small osteochondral defects
2005
Stem Cell Therapy for the treatment of gastroenterology, dermatology, and immune-based diseases
2004
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - TiGenix

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Tigenix Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of TiGenix

TiGenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Regenerative and gene therapeutics for heart failure are developed.
domain founded_year HQ Location
Developer of autologous cell therapies
domain founded_year HQ Location
Provider of tools for the analysis of RNA structures
domain founded_year HQ Location
Specialized drugs are developed for genetic heart diseases.
domain founded_year HQ Location
Developer of antiviral agents against targets in the treatment of hepatitis
domain founded_year HQ Location
Therapeutics for heart and cardiovascular diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about TiGenix

When was TiGenix founded?

TiGenix was founded in 2000 and raised its 1st funding round 6 years after it was founded.

Where is TiGenix located?

TiGenix is headquartered in Leuven, Belgium. It is registered at Leuven, Flemish Brabant, Belgium.

Is TiGenix a funded company?

TiGenix is a funded company, having raised a total of $19M across 15 funding rounds to date. The company's 1st funding round was a Post-IPO of $9.25M, raised on Jan 05, 2006.

What does TiGenix do?

TiGenix was established in 2000 in Leuven, Belgium, within the biotechnology sector. A proprietary platform of donor-derived expanded adipose-derived stem cells is employed to develop therapeutics. Key programs include Cx601 for perianal fistulas in Crohns disease and Cx611 for rheumatoid arthritis and sepsis. AlloCSC-01 involves allogeneic cardiac stem cells for acute ischaemic heart disease. ChondroCelect, approved for knee cartilage repair, is commercialized in Europe.

Who are the top competitors of TiGenix?

TiGenix's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.

How many acquisitions has TiGenix made?

TiGenix has made 2 acquisitions, including Cellerix, and Orthomimetics.

Who are TiGenix's investors?

TiGenix has 16 investors. Key investors include Takeda Pharmaceuticals, RA Capital, Kreos Capital, European Union, and Capricorn Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available